Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Other financing activities (2020 - 2024)

RxSight (RXST) has disclosed Other financing activities for 5 consecutive years, with $391000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Other financing activities rose 167.65% year-over-year to $391000.0, compared with a TTM value of $391000.0 through Dec 2025, down 49.09%, and an annual FY2024 reading of $768000.0, down 65.64% over the prior year.
  • Other financing activities was $391000.0 for Q3 2024 at RxSight, up from $377000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.6 million in Q4 2023 and bottomed at -$578000.0 in Q3 2023.
  • Average Other financing activities over 5 years is $339153.8, with a median of $292000.0 recorded in 2022.
  • The sharpest move saw Other financing activities skyrocketed 14650.0% in 2022, then crashed 295.93% in 2023.
  • Year by year, Other financing activities stood at $687000.0 in 2020, then plummeted by 98.84% to $8000.0 in 2021, then surged by 3550.0% to $292000.0 in 2022, then skyrocketed by 443.84% to $1.6 million in 2023, then plummeted by 75.38% to $391000.0 in 2024.
  • Business Quant data shows Other financing activities for RXST at $391000.0 in Q3 2024, $377000.0 in Q2 2024, and $1.6 million in Q4 2023.